KIKateryna Iaremenko

Kateryna Iaremenko

*This is an algorithmically generated author record based on publicly available information.

Kateryna Iaremenko has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of multiplex PCR analysis for the simultaneous detection of various urogenital infections in men with symptoms of urethritis

    by O.P. Shevchenko, P.V. Bardov, O.YU. Matsas, O.I. Mulkina, K.M. Iaremenko, O.V. Vorobiova

    Objective — to determine the spectrum and assess the detection frequency of various urogenital infections among hetero-sexual male patients with inflammatory diseases of the urogenital tract. Materials and methods. The study group included 95 men aged 20—62 years (mean age (34 ± 2.7) years). First-void urine samples and genital discharge specimens were collected. Samples were examined using the multiplex test system Allplex STI Essential Assay (Seegene, South Korea) for detection of Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) using the polymerase chain reaction (PCR) method. Results and discussion. Molecular biological testing revealed one or more sexually transmitted infections in all patients across different age groups presenting with urethritis symptoms. The prevalence rates were as follows: UP — 32.6 %, UU — 28.4 %, MG — 10.5 %, MH — 8.4 %, CT — 9.5 %, NG — 4.2 %, TV — 5.3 %. Combined STIs were detected in 14.7 % of patients. Across all age groups, Ureaplasma species showed the highest prevalence: UP — 18—30 years: 22.7 %, 31—45 years: 34.2 %, 46—62 years: 34.4 %; UU — 18—30 years: 16.1 %, 31—45 years: 28.7 %, 46—62 years: 51.7 %. CT and NG were detected only in the 18—30 years (12.9 %, 9.6 %) and 31—45 years (14.2 %, 2.8 %) age groups. MG was identified both as a single causative agent of urethritis and in mixed infections with Ureaplasma species. TV was detected only in mixed infections with Ureaplasma and Mycoplasma species and was present in all age groups. A significant number of co-infections were found in the third group of examined men aged 46—62 years. Conclusions. Male urethritis is an inflammation of the urethra and paraurethral glands. It is classified as gonococcal or nongonococcal urethritis. The most common causative agents include CT, NG, MG, MH, UU, UP, and TV. Clinical symptoms of urethritis are not specific to a single microorganism; therefore, screening strategies should consider multiple infectious agents. Multiplex PCR is a rapid and effective method for the diagnosis of urethritis. Sexually transmitted infections are a global public health problem due to their high prevalence and frequent occurrence of co-infections. Timely detection of infectious agents in the urogenital tract is crucial for the prevention of STIs.

  • Open Access

    Pleuropulmonary Manifestations in Patients with Systemic Lupus Erythematosus

    by O.B. Iaremenko, D.I. Koliadenko, K.M. Iaremenko, N.D. Kozak, O.V. Dema, Д.і. Коляденко

    Objective — to assess the prevalence of non-infectious pleuropulmonary manifestations in patients with systemic lupus erythematosus (SLE), as well as the demographic, clinical and laboratory characteristics of such patients. Materials and methods. A total of 435 patients with SLE (87.5 % female; median age 37 (26—49) years) were enrolled in a cross-sectional study, including 200 with pleuropulmonary manifestations and 235 without them. Patients were evaluated for demographic details, clinical SLE manifestations, SLE Disease Activity Index 2000 (SLEDAI-2K), SLICC/ACR Damage Index (DI). Laboratory evaluations included complete blood count with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), interleukin-6 (IL-6), IL-10, complement C3 and C4 levels, specific autoantibodies. Procalcitonin and presepsin serum levels were measured to exclude infections. Results and discussion. At least one pleuropulmonary manifestation occurred in 46 % of patients, with pleurisy being the most frequent (24 %). Respiratory involvement was associated with male sex, longer disease duration, and older age at disease onset. Patients with respiratory complications had higher SLEDAI-2K and SLICC/ACR DI scores than those without pleuropulmonary involvement. Patients with pleuropulmonary manifestations more frequently exhibited lymphadenopathy, nephritis, pericarditis, other cardiac manifestations, fever, weight loss, anemia, and thrombocytopenia; conversely, cutaneous manifestations occurred less frequently in patients with pleuropulmonary involvement. Patients with respiratory involvement were found to have higher levels of ESR, CRP, hs-CRP, and IL-6. A higher frequency of positive anti-La/SSB, antiphospholipid, and anti-chromatin antibodies was observed in patients with pleuropulmonary manifestations compared to those without them.In multivariate logistic analysis, respiratory involvement was positively associated with older age (odds ratio (OR) 1.03 (95 % confidence interval (CI) 1.01—1.05), p = 0.004), higher SLEDAI-2K (OR 1.05 (95 % CI 1.01— 1.09), p = 0.030) and SLICC/ACR DI scores (OR 11.34 (95 % CI 1.03—1.74), p = 0.027), presence of lymphadenopathy (OR 2.27 (95 % CI 1.33—3.88), p = 0.003), pericarditis (OR 4.40 (95 % CI 2.29—8.46), p < 0.001), other cardiac manifestations (OR 10.1 (95 % CI 5.65—17.9), p < 0.001), and systemic symptoms (OR 2.14 (95 % CI 1.24—3.70), p = 0.007). Cutaneous manifestations were, on the other hand, negatively associated with the occurrence of pleuropulmonary symptoms (OR 0.27 (95 % CI 0.15—0.50), p < 0.001). Conclusions. Pleuropulmonary manifestations are frequent in SLE, particularly pleuritis. Respiratory involvement is associated with male sex, older age, longer disease duration, and occurs mainly in patients with active and severe lupus, often with previous or concomitant major organ involvement other than lungs. Patients with pleuropulmonary involvement have higher levels of inflammatory markers and higher frequency of positive anti-La/SSB, antiphospholipid, and anti-chromatin antibodies.

  • Open Access

    Lupus nephritis: clinical characteristics, serological associations, pattern of pro- and anti-inflammatory markers

    by O. Iaremenko, D. Koliadenko, K. Iaremenko, I. Matiyashchuk

    The present study aimed to investigate the prevalence, clinical, and laboratory characteristics of renal involvement in a large cohort of Ukrainian patients with systemic lupus erythematosus (SLE). Methods. A total of 380 patients with SLE were enrolled in this cross-sectional study, including 176 with lupus nephritis (LN) and 204 with non-renal SLE. Patients were reviewed for demographic details, clinical SLE manifestations, SLE Disease Activity Index 2000 (SLEDAI-2K), and SLICC/ACR Damage Index. Laboratory evaluations included complete blood count with an erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), anti-CRP antibodies, serum creatinine, complement C3 and C4 levels, urinalysis, 24-hour urine protein, specific autoantibodies, interleukin-6 (IL-6), IL-10. Results. There was a significantly higher frequency of malar rash, lymphadenopathy, splenomegaly, serositis, pulmonitis, fever, necrotizing vasculitis, and a history of arterial/venous thrombosis in patients with LN; while Raynaud’s phenomenon, Sjogren’s syndrome, peripheral nervous system manifestations occurred more often in patients with non-renal SLE. Patients with LN were found to have higher ESR levels and lower IL-10 levels. Either frequency of anti-dsDNA positivity and its titer were higher in the LN group with no differences regarding other autoantibodies. C3 and C4, CRP, hs-CRP, anti-CRP, and IL-6 levels showed no significant difference between the groups. Multivariate analysis demonstrated that LN was positively associated with pulmonitis (OR 5.34 (95% CI 1.88-15.10), p=0.002), arterial/venous thrombosis (OR 6.80 (95% CI 1.87-24.70), p=0.004), anti-dsDNA positivity (OR 6.22 (95% CI 1.89-20.50), p=0.003), higher SLEDAI-2K score (OR 1.15 (95% CI 1.08-1.23), p<0.001) and negatively associated with Raynaud’s syndrome (OR 0.20 (95% CI 0.08-0.49), p<0.001) and younger age at disease onset (OR 0.96 (95% CI 0.93-0.99), p=0.003). In the LN group, 27 patients (15.3%) had nephrotic syndrome. In multivariate logistic analysis, male sex (OR 5.21 (95% CI 1.77-15.30), p=0.003) and higher SLICC/ACR score (OR 2.12 (95% CI 1.45-3.09), p<0.001) were associated with increased risk of nephrotic syndrome, whereas lymphadenopathy (OR 0.31 (95% CI 0.12-0.80), p=0.02) was associated with decreased risk of nephrotic syndrome development. Conclusions. Our cohort of Ukrainian LN patients showed different characteristics in demographic, clinical, and laboratory findings compared to patients with non-renal SLE. These features are mostly on par with LN patients of other nationalities around the world.


  • Bone turnover biomarkers, disease activity, and MRI changes of sacroiliac joints in patients with spondyloarthritis

    by Oleg Iaremenko, Iuliia Shynkaruk, Dmytro Fedkov, Kateryna Iaremenko, Liubov Petelytska

    The lack of valid biomarkers in patients with spondyloarthritis (SpA) requires searching for additional options to increase sacroiliac joint (SIJ) evaluation effectiveness. We assessed the serum levels of bone turnover markers and their relationships with active and chronic changes in SIJs using magnetic resonance imaging (MRI), indices, and laboratory parameters of disease activity in SpA patients. 102 patients with SpA and 15 healthy subjects were included. Testing of serum levels of transforming growth factor-beta (TGF-β1), Wnt3, sclerostin, and Dickkopf-1 (Dkk-1) was conducted. Active inflammatory lesions in SIJs were evaluated using Spondyloarthritis Research Consortium of Canada (SPARCC) MRI SIJ score, and chronic changes using the Danish scoring method. Bath Ankylosing Spondylitis Disease Activity Index, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Ankylosing Spondylitis Disease Activity Scores with CRP, and ESR were used to assess disease activity. Serum levels of Dkk-1, TGF-β1, and sclerostin were significantly lower in SpA patients compared to healthy controls. The serum levels of Dkk-1 positively correlated with CRP. Dkk-1 had a significant negative correlation with Danish score. The sclerostin serum level had a weak negative correlation with the active inflammatory MRI SIJ lesions. There were positive correlations between TGF-β1 and sclerostin with Dkk-1, and negative correlation between Wnt3 and sclerostin. Dkk-1 positively correlated with CRP and negatively with chronic SIJ changes by Danish score. Sclerostin negatively correlated with the active SIJ lesions by SPARCC. This suggests that Dkk-1 and sclerostin are the most promising candidates to reveal inflammation and bone turnover in patients with SpA.


  • Open Access

    THU0404 DICKKOPF-1 SERUM LEVELS AND THEIR CORRELATION WITH ACTIVE AND CHRONIC MRI-CHANGES OF SACROILIAC JOINTS AND CLINICAL INDICES IN PATIENTS WITH SPONDYLOARTHRITIS

    by Iuliia Shynkaruk, Oleg Iaremenko, Dmytro Fedkov, Kateryna Iaremenko

    Background The lack of valid biochemical markers for spondyloarthritis (SpA) patients requires searching the additional options to increase sensitivity of clinical and radiological methods in validation of changes in sacroiliac joints (SIJ). The molecular basis for the link between inflammation and new bone formation in SpA is still not clear. It has recently been shown that low serum levels of the Dickkopf-1 (Dkk-1), the natural inhibitor of Wnt protein, is associated with the formation of new syndesmophytes in patients with SpA [1]. Dkk-1 may be a main factor in blocking new bone formation [2], and might play a role of potential biomarker in SpA patients. Objectives To determine the serum levels of Dkk-1 and their relationship with active and chronic changes in SIJ on MRI, indices and laboratory parameters of disease activity and functional status in SpA patients. Methods This study includes 105 SpA patients (89.5% HLA B27 positive) and 15 healthy age- and gender- matched controls. Dkk-1 serum levels (pmol/l) were conducted by ELISA. Active inflammatory lesions in SIJ were evaluated by Spondyloarthritis Research Consortium of Canada (SPARCC) MRI SIJ score (0-72, n=69) and chronic changes by Danish scoring method (0-48). Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, mm), Bath Ankylosing Spondylitis Functional Index (BASFI, mm), C-reactive protein (CRP, mg/l) and erythrocyte sedimentation rate (ESR, mm/hr) were recorded. Statistical analysis was performed using Spearman correlation coefficient, Student t-test and receiver operating characteristic (ROC) curves. Results Mean value (M±σ) of Dkk-1 was 45.1±36.3. The mean value of indices and laboratory parameters were: BASDAI – 44.5±19.3, BASFI – 31.1±23.1, CRP – 20.6±31.3, ESR – 26.8±22.0. SPARCC score was 22.2±12.0, Danish score – 19.5±9.83. Dkk-1 serum levels were lower (P < 0.01) in SpA patients compare with the controls. ROC analysis indicated that the AUC for Dkk-1 is 0.88±0.05 (pConclusion Dkk-1 levels are significantly lower in SpA patients compare with healthy controls and has a strong association with SpA. Dkk-1 significantly negatively correlates with chronic changes in SIJ on MRI, that may confirm that deficiency of Dkk-1 could increase progression of pathological changes in SIJ. Dkk-1 correlates only with CRP level, but none of the other indices and laboratory parameters of disease activity and functional status. References [1] Song I-H. Ann Rheum Dis. 2011; 70: 1257-1263. [2] Zhao Z. Clin Rheumatol. 2018. doi: 10.1007/s10067-018-4284-y. Disclosure of Interests Iuliia Shynkaruk: None declared, Oleg Iaremenko: None declared, Dmytro Fedkov Grant/research support from: MSD, AbbVie, ProPharma, Laboratoires Expanscience;, Consultant for: MSD, AbbVie, ProPharma, Laboratoires Expanscience;, Speakers bureau: Janssen, Kateryna Iaremenko: None declared

  • Open Access

    FRI0288 OPHTHALMOLOGICAL MANIFESTATIONS AND ENDOTHELIN-1 PLASMA LEVELS IN PATIENTS WITH SYSTEMIC NECROTIZING VASCULITIS (SNV)

    by Liubov Petelytska, Oleg Iaremenko, Kateryna Iaremenko

    Background: Inflammatory eye disease is described in 50% to 60% of patients with ANCA-positive vasculitis and in 10–20% of patients with polyarteritis nodosa, and for 8% to 16% of patients it is an initial manifestation [1,2]. Endothelin-1 (ET-1) as a potential participant in the local regulation of intraocular pressure, ocular blood vessel tone, and iris smooth muscle tone, suggesting that it may be an important mediator in the development of ocular pathologic conditions [3]. The lower ET-1 plasma levels were found in the optic neuropathy [4]. Objectives: to provide a more complete description of the ocular disease in patients with systemic necrotizing vasculitis (SNV), to evaluate the serum level of ET-1 in patients with SNV with and without eye involvement. Methods: The study included 36 patients with SNV (polyarthritis nodosa - 8, ANCA - associated vasculitis - 28) and healthy controls (n=26). The 17 patients with SNV had ophthalmological manifestations. Clinical activities of patients were calculated according to the Birmingham Vasculitis Activity Score (BVAS). The serum levels of ET-1 (pmol/L) were determined by immunoassay analysis using the kits of Biomedica. The outcomes of this study were the differences in marker levels between SNV patients with and without eye involvement and healthy controls estimated by analysis of the absolute changes in marker levels and the areas under receiver operating characteristic (ROC) curves (AUC). Results: The ocular manifestation of patient with SNV included episcleritis (n=10), anterior uveitis (n=3), ischaemic optic neuritis (n=3) and occlusive retinal vasculitis (n=1). All patients had active disease (BVAS>11). There were no significant differences of BVAS, ESR and CRP between SNV patients with and without eye involvement. In 14% patients with SNV eye involvement was an initial manifestation. The level of ET-1 (M ± σ) in group of SNV patients with eye involvement (n=17) was 0.28 ± 0.13 and did not differ significantly from the control group (0.27 ± 0.10, p> 0.05). At the same time, in patients without eye involvement (n=19), it was significantly elevated (0.36 ± 0.34) compared with control group and with group of SNV patients with eye involvement (p < 0,001). ROC analysis showed that the AUC for ET-1 is 0.5±0.10 (p=0.98), which indicates not acceptable capacity for ET-1 differentiate groups of patients with ocular involvement and patients without ocular involvement (sensitivity - 59%, specificity - 57%). Conclusion: The most common ocular manifestation in patients with SNV was episcleritis, which occurred in almost one third of patients. The serum levels of ET-1 were decreased in patients with SNV with eye involvement compared with patients without eye involvement, but this cannot be used for diagnostic purposes. References: [1] Pakrou N, Selva D, Leibovitch I. Wegener’s granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum. 2006;35(5):284–92. [2] Pagnoux, C., Seror, R., Henegar, C., Mahr, A., Cohen, P., Le Guern, V., Bienvenu, B., Mouthon, L., and Guillevin, L. (2010). Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis and Rheumatism, 62, 616–26 [3] Sugiyama T. Involvement of Endothelin-1 in the Pathophysiology of Normal-Tension Glaucoma. International Journal of Ophthalmic Research 2015; 1(2): 36-40 Available from: URL: http://www.ghrnet.org/index.php/ijor/article/view/1221. [4] Ohguro I, Ohguro H, Ohkuro K, Nakazawa M: Study of contribution of low levels of plasma endothelin-1 concentrations to pathogenesis of glaucomatous optic neuropathy. Hirosaki Med J, 2006; 57: 59–64 Disclosure of Interests: None declared

  • Open Access

    AB0690 Diagnostic values of endothelin-1 in patients with systemic necrotizing vasculitis

    by L. Petelytska, O. Iaremenko, K. Iaremenko

    Background Systemic necrotizing vasculitis (SNV) is characterised by destructive and inflammatory changes in the vessels. Binding of autoantibodies and immune complexes on the surface of endothelial cells stimulates the synthesis of endothelin-1 (ET-1), which leads to activation of macrophages and adhesion of neutrophils, remodelling of the vascular wall and its damage. Objectives To evaluate the serum level of ET-1 in patients with SNV and the possibility of its using for the diagnosis of SNV and involvement of individual organs. Methods The study included 36 patients with SNV (polyarthritis nodosa – 8, ANCA – associated vasculitis – 28) and healthy controls (n=26). Clinical activities of patients were calculated according to the Birmingham Vasculitis Activity Score (BVAS). All patients had active disease (BVAS >11). The serum levels of ET-1 (pmol/L) were determined by immunoassay analysis using the kits of Biomedica. The outcomes of this study were the differences in marker levels between patients with active SNV and healthy controls, patients with different forms of vasculitis, with varying degrees of BVAS activity, with involvement different organs and systems estimated by analysis of the absolute changes in marker levels and the areas under receiver operating characteristic (ROC) curves (AUC). Results The level of ET-1 (M±σ) in the general group of patients with SNV was 0.31±0.24 and did not differ significantly from the control group (0.27±0.10, p>0.05). At the same time, in patients who did not receive at screening glucocorticoids and cytotoxic agents (n=9), it was significantly elevated (0.62±0.58, p=0.03). However, ROC analysis indicated the moderate sensitivity (67%) and the low specificity (48%) of ET-1 for diagnosis of SNV. There were no significant differences in the levels of ET-1 between patients with different forms of vasculitis and with varying degrees of BVAS activity. In the analysis of the values of the ET-1 depending on the involvement of different organs and systems, it was found that only in patients with kidney involvement (n=15) its level (0.40±0.33) was significantly higher compared with patients without kidney involvement (0.28±0.22, p=0.04) and control group (pConclusions The serum levels of ET-1 were elevated in patients with SNV with kidney involvement (48% compared to healthy controls and 43% compared with patients without kidney involvement), which can be used for diagnostic purposes. Disclosure of Interest None declared

  • SAT0404 Relationship of sclerostin and DICKKOPF-1 serum levels with disease activity and inflammatory MRI lesions in patients with spondyloarthritis

    by I Shynkaruk, O Iaremenko, D Fedkov, K Iaremenko

    Background Dickkopf-1 (Dkk-1) and sclerostin (Scl) are likely to play important roles in the process of ankylosis in Spondyloarthritis (SpA) [1]. Their serum levels are associated with the formation of new syndesmophytes [2]. But the relationship between these biomarkers and disease activity including active inflammatory lesions in sacroiliac joints (SIJ) on magnetic resonance imaging (MRI) still not clear. Objectives To estimate the relationship between the Scl and Dkk-1serum levels and active inflammatory MRI lesionsin SIJ, disease activity and functional status in SpA patients (pts). Methods Serum levels of Scl and Dkk-1 (pmol/l; ELISA) were measured at baseline in 79 pts with SpA. Mean age of pts (63.3% male) was 37.5±11.3, mean disease duration – 10.7±9.44 yrs. Radiological sacroiliitis defined according to Kellgren grade was: 0 – 1.6%, I – 22%, II – 49.2%, III – 13.6% and IV – 13.6%. Active inflammatory lesions in SIJ were evaluated with Spondyloarthritis Research Consortium of Canada (SPARCC) MRI SIJ score (0–72, n=46). Disease activity was measured by Ankylosing Spondylitis Disease Activity Score (ASDAS) using C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, mm), CRP (mg/l) and erythrocyte sedimentation rate (ESR, mm/hr). Functional status estimated using Bath Ankylosing Spondylitis Functional Index (BASFI, mm). For correlation the Spearman correlation coefficient was calculated. Results Mean value (M±σ) of biomarkers in all SpA pts were: Scl – 19.2±11.63, Dkk-1 – 30.7±19.5. The mean value of indices and laboratory parameters in all SpA pts were: ASDAS-CRP – 3.01±1.09, BASDAI – 4.36±1.88, CRP – 20.3±33.0, ESR – 25.8±20.7, BASFI – 3.01±2.33. SPARCC score was 24.6±10.9. Scl level was significantly higher in pts with lower activity by SPARCC score (23.1±12.7) vs higher activity (16.6±7.63), p=0.043, in pts with moderate disease activity by ASDAS-CRP (22.3±15.6) vs very high disease activity (14.6±9.89), p=0.031, and in women (23.1±12.6) vs men (16.9±10.5), p=0.014. Its level didn't depend on CRP, ESR, BASDAI, BASFI and HLA B27 positivity. Scl showed significantly negative correlation with BASDAI (r=-0.381, p=0.041) only in women. There was no difference in Dkk-1 serum level depending on the gender, disease activity (by ASDAS-CRP), functional status, the presence of HLA B27 and inflammatory changes in SIJ (with quartile distribution). But the correlation analysis showed significant relationship of Dkk-1 with CRP (r=0.243, p=0.031) and SPARCC MRI SIJ score (r=0.351, p=0.017). The strength of the correlation between Dkk-1 and CRP was slightly higher in HLA B27 positive pts (90%; r=0.334, p=0.018). In SpA pts with lower activity by SPARCC score significant correlation between Dkk-1 and inflammatory lesions in SIJ (r=0.400, p=0.043) and a negative correlation between Dkk-1 and BASDAI (r=-0.513, p=0.017) were found. There was no correlation between Scl and Dkk-1 levels among all pts and different subgroups. Conclusions Scl level is significantly higher in pts with lower disease activity by SPARCC MRI SIJ score and ASDAS-CRP. Dkk-1 significantly positively correlates with disease activity due to CRP level and SPARCC score, but not to BASDAI. References Xie W. Ann N Y Acad Sci. 2016 Jan; 1364: 25–31. Song I-H. Ann Rheum Dis. 2011 Jul 1; 70(7): 1257–1263. References Disclosure of Interest None declared

  • FRI0340 B-cell activating factor as a biomarker of activity of systemic necrotizing vasculitis (SNV)

    by L Petelytska, O Iaremenko, K Iaremenko

    Background Non-specific marker of inflammation such as C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) have limited value in assessment of vasculitis activity. Normal ESR values do not exclude the diagnosis of active vasculitis, and its increase may be due to concomitant infection. Objectives To evaluate the levels of B-cell activating factor and ESR in pts with different activity of SNV. Methods The serum levels of B-cell activating factor (BAFF) and ESR were measured in 48 pts with SNV (granulomatosis with polyangiitis – 22, eosinophilic granulomatosis with polyangiitis – 9, microscopic polyangiitis – 6, polyarteritis nodosa – 11). The 48 pts included 18 male and 30 female with median age 49; 24 were positive for cytoplasmic antineutrophil cytoplasmic antibodies and 11 for perinuclear antineutrophil cytoplasmic antibodies. At screening, 9 pts were without any treatment, 26 pts were receiving glucocorticoids (GCs) and 13 pts were receiving some cytotoxic agents and GCs. Clinical activities of pts were calculated by the Birmingham Vasculitis Activity Score (BVAS). All pts were divided into 3 groups according to the value of BVAS: group 1 (BVAS≤11; n=12), group 2 (BVAS =12–23; n=23) and group 3 (BVAS≥24; n=13). The outcomes of this study were the differences in marker levels between groups estimated by analysis of the absolute changes in marker levels and the areas under receiver operating characteristic (ROC) curves. Results The levels of BAFF were significantly higher in group 3 (0.88±0.19 ng/ml) compared with group 1 (0.68±0.13 ng/ml, pConclusions There are significant differences in levels of BAFF between pts with BVAS≥24 and pts with BVAS≤11. According to ROC analysis evaluation of serum BAFF level distinguishes pts with active SNV from pts with low activity or remission better than determination of ESR. Disclosure of Interest None declared

  • FRI0268 Changes in Serum Levels of the Biomarkers of Vascular Wall Damage in the Treatment of Systemic Necrotizing Vasculitis (SNV)

    by L. Petelytska, O. Iaremenko, K. Iaremenko

    Background SNV are a group of rare conditions characterized by inflammation and necrosis of blood vessel walls. Despite current immunosuppressive treatment of SNV their clinical course and outcome are highly variable. That's why searching new biomarkers that may be useful for determining vasculitis activity, responding to treatment and risk of relapse are needed. Objectives To identify serum levels of the biomarkers of vascular wall damage before and after induction treatment of SNV. Methods Three serum proteins (alpha actin 2 (α-SMA), endothelin-1 (ET-1) and elastin) representing damage of blood vessel walls and anti-neutrophil cytoplasmic antibodies (ANCA) titres were measured in 22 pts with SNV (granulomatosis with polyangiitis – 12, eosinophilic granulomatosis with polyangiitis – 2, microscopic polyangiitis – 3, polyarteritis nodosa – 5) before induction treatment and at 6.75±3.33 (M ± SD) months after the beginning of induction therapy, and also in 26 healthy controls. The 22 pts included 6 male and 16 female with median age 48.8±10.5 years. Pts received induction therapy based on EULAR Recommendations for the Management of Primary Small and Medium Vessel Vasculitis (2009). Clinical activities of pts were calculated according to the Birmingham Vasculitis Activity Score (BVAS). All pts with SNV after induction treatment were divided into group of responding to treatment (decrease BVAS in 5 and more points, group1, n=17) and group of non-adequate response to treatment (without decrease BVAS in 5 and more points, group 2, n=5). The outcomes of this study were the differences in markers levels in pts with SNV before and after induction treatment, and also the differences in markers levels between pts with responding to treatment and pts with non-adequate response to treatment estimated by analysis of the absolute changes in markers levels. Results The mean BVAS in pts before treatment was 20.7±6.09 and 7.47±8.01 - after treatment (4.29±3.60 in group 1 and 22.3±5.03 in group 2). The titers of ANCA were elevated in 72.7% of pts before treatment and remained elevated in 54.5% of pts during treatment. There were no differences in levels of ET-1 and elastin in pts with SNV before treatment and controls, and also after induction treatment. The levels of α-SMA were significantly higher (by 52%) in pts with active SNV (94.1±87.8 ng/ml) compared with controls (44.7±25.7 ng/ml, pConclusions The levels of serum α-SMA are elevated in severe active SNV. There are significant differences in levels of this marker before and approximately at 7 months after beginning of induction therapy in pts with SNV, especially in pts with responding to treatment. α-SMA hasn't shown differences before and approximately at 7 months after beginning of induction therapy in pts with non-adequate clinical response to treatment. This biomarker may be useful for estimating response to treatment in pts with SNV, but the future researches are needed. Disclosure of Interest None declared